Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Reviva Pharmaceuticals Holdings Inc.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.